Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis-Reference-Cited by-同舟云学术

Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis

Published:2017-02-13 Issue:12 Volume:47 Page:1317-1328
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Okura Yasushi¹,Namisaki Tadashi²,Moriya Kei²,Kitade Mitsuteru²,Takeda Kosuke²,Kaji Kosuke²,Noguchi Ryuichi²,Nishimura Norihisa²,Seki Kenichiro²,Kawaratani Hideto²,Takaya Hiroaki²,Sato Shinya²,Sawada Yasuhiko²,Shimozato Naotaka²,Furukawa Masanori²,Nakanishi Keisuke²,Saikawa Soichiro²,Kubo Takuya²,Asada Kiyoshi²,Yoshiji Hitoshi²

Affiliation:

1. Department of Endoscopy and Ultrasound; Nara Medical University; Kashihara Nara Japan

2. Third Department of Internal Medicine; Nara Medical University; Kashihara Nara Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12860/fullpdf

Reference42 articles.

1. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study;Bedogni;Hepatology,2005

2. Non-alcoholic fatty liver disease: the mist gradually clears;Alwis;J Hepatol,2008